High Expression of CCL20 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma after Curative Resection
High Expression of CCL20 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma after Curative Resection
复制标题
DOI：
10.1007/s11605-011-1775-4
复制
发表时间：
2012-04-01
影响因子：
3.2
通讯作者：
Hu, Sanyuan
中科院分区：
文献类型：
--
作者：
Ding, Xiangjiu;Wang, Kexin;Hu, Sanyuan
趋化因子配体20（CCL20）在恶性肿瘤的发生、侵袭和进展中发挥着重要作用。本研究旨在探讨CCL20对肝细胞癌(HCC)根治性切除术后患者预后的意义。采用免疫组织化学方法评估了125例接受根治性切除HCC的患者肿瘤组织中CCL20的表达。分析CCL20表达与临床病理特征之间的关系。通过单因素和多因素分析评估其对HCC患者肿瘤复发和生存的预测价值。所有肿瘤标本中均验证了CCL20的表达。 CCL20表达与肿瘤大小（P = 0.002）、肿瘤数量（P = 0.031）、血管侵犯（P = 0.003）、肿瘤分化（P = 0.024）和肿瘤复发（P < 0.001）相关。 CCL20高表达患者的无复发生存率和总生存率均低于CCL20低表达患者（P均<0.001）。多变量分析显示CCL20表达是肿瘤复发（风险比3.934，P=0.002）、无复发生存（风险比2.573，P=0.001）和总生存（风险比2.930，P=0.001）的独立预测因子。CCL20表达与HCC患者的肿瘤复发和生存相关。它可用于预测HCC患者的预后，并可能成为术后辅助治疗的新靶点。
Chemokine ligand 20 (CCL20) plays an important role in the carcinogenesis, invasion, and progression of malignancies. This study aimed to investigate the prognostic significance of CCL20 in patients with hepatocellular carcinoma (HCC) after curative resection.Expression of CCL20 was evaluated by immunohistochemistry in tumor tissue from 125 patients who underwent curative resection of HCC. The relationship between CCL20 expression and clinicopathologic features was analyzed. Univariate and multivariate analyses were performed to evaluate its predictive value for tumor recurrence and survival of HCC patients.CCL20 expression was verified in all tumor specimens. CCL20 expression was associated with tumor size (P = 0.002), tumor number (P = 0.031), vascular invasion (P = 0.003), tumor differentiation (P = 0.024), and tumor recurrence (P < 0.001). Patients with high CCL20 expression had poorer recurrence-free survival and overall survival (both P < 0.001) than those with low CCL20 expression. Multivariate analysis showed CCL20 expression was an independent predictor of tumor recurrence (Hazard ratio 3.934, P = 0.002), recurrence-free survival (Hazard ratio 2.573, P = 0.001), and overall survival (Hazard ratio 2.930, P = 0.001).CCL20 expression was associated with tumor recurrence and survival of HCC patients. It may be used to predict prognosis of patients with HCC and may be a new target of postoperative adjuvant therapy.